Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Inventory (2022 - 2025)

Historic Inventory for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to $22.4 million.

  • Arcutis Biotherapeutics' Inventory rose 5996.43% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year increase of 5996.43%. This contributed to the annual value of $14.5 million for FY2024, which is 1059.84% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Inventory of $22.4 million as of Q3 2025, which was up 5996.43% from $16.3 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Inventory ranged from a high of $22.4 million in Q3 2025 and a low of $4.3 million during Q3 2022
  • Over the past 4 years, Arcutis Biotherapeutics' median Inventory value was $13.9 million (recorded in 2024), while the average stood at $13.0 million.
  • Its Inventory has fluctuated over the past 5 years, first skyrocketed by 22303.23% in 2023, then skyrocketed by 73.31% in 2024.
  • Arcutis Biotherapeutics' Inventory (Quarter) stood at $7.5 million in 2022, then soared by 74.79% to $13.1 million in 2023, then grew by 10.6% to $14.5 million in 2024, then skyrocketed by 54.34% to $22.4 million in 2025.
  • Its last three reported values are $22.4 million in Q3 2025, $16.3 million for Q2 2025, and $16.6 million during Q1 2025.